Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 trial

Clinical Genitourinary Cancer

Volumn 11, Issue 2, 2013, Pages 128-133

  Blesius, Aurore ^a   Beuselinck, Benoit ^b   Chevreau, Christine ^c   Ravaud, Alain ^d   Rolland, Frédéric ^e   Oudard, Stéphane ^b   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d University Hospital   (France)

^e Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

Author keywords

Everolimus; Renal cell carcinoma; Sequential therapy; Tyrosine kinase inhibitor

Indexed keywords

DOVITINIB; EVEROLIMUS; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FRANCE; HUMAN; KIDNEY METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; QUINOLONES; SALVAGE THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84876982983     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.12.001     Document Type: Article

References (29)

1. I. Tamaskar, J. Dhillon, R. Pili Resistance to angiogenesis inhibitors in renal cell carcinoma Clin Adv Hematol Oncol 9 2011 101 110
2. G. Bergers, D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
3. Serova M, Riveiro ME, Dokmak S, et al. Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib; 102nd Annual Meeting of the American Association of Cancer Research; 2011; Orlando, FL. Abstract 4488
4. O. Casanovas, D.J. Hicklin, G. Bergers Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
5. C.C. Hudson, M. Liu, G.G. Chiang Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
6. V.A. Robb, M. Karbowniczek, A.J. Klein-Szanto Activation of the mTOR signaling pathway in renal clear cell carcinoma J Urol 177 2007 346 352
7. G.V. Thomas, C. Tran, I.K. Mellinghoff Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 2006 122 127
8. R.J. Motzer, B. Escudier, S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
9. R.J. Motzer, B. Escudier, S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
10. Grünwald V, Miller K, Machiels J, et al. An international expanded access program (EAP) of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy; 35th Congress of the European Society for Medical Oncology (ESMO); 2012; Italy, Milan 2010. Abstract 877PD.
11. Kidney cancer National Comprehensive Cancer Network Clinical Practice guidelines in Oncology-v.2. 2011. National Comprehensive Cancer Network [Web site] http://wwww.nccn.org Accessed: February 1, 2011
12. B. Ljungberg, N.C. Cowan, D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
13. B. Escudier, V. Kataja ESMO Guidelines Working Group ESMO guidelines working group Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 81 82
14. T.M. de Reijke, J. Bellmunt, H. van Poppel EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 2009 765 773
15. I.N. Zama, T.E. Hutson, P. Elson Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
16. R.J. Motzer, J. Bacik, B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
17. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
18. B. Escudier, C. Szczylik, T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
19. M.P. Sablin, S. Negrier, A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
20. A.Z. Dudek, J. Zolnierek, A. Dham Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
21. G. Di Lorenzo, G. Cartenì, R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
22. J.A. Garcia, T.E. Hutson, P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
23. M. Schmidinger, J. Bellmunt Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma Cancer Treat Rev 36 2010 416 424
24. S. Oudard, A. Ravaud, B. Escudier Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: focus on mechanism of action Ann Urol 1 2010 11 19
25. B.I. Rini New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance Clin Cancer Res 16 2010 1348 1354
26. E. Angevin, C. Lin, A. Pande A phase I/II study of dovitinib (TKI258), and FGFR and VEGFR inhibitor, in patients with advanced or metastatic renal cell cancer: phase I results J Clin Oncol 28 suppl 2010 abstract 305
27. ClinicalTrials.gov Study of dovitinib versus sorafenib in patients with metastatic renal cell carcinoma http://www.clinicaltrials.gov/ct2/show/ NCT01223027?term=NCT01223027&rank=1 Accessed: December 28, 2012
28. ClinicalTrials.gov Sequential study to treat renal cell carcinoma http://www.clinicaltrials.gov/ct2/show/NCT00732914?term=NCT00732914&rank=1 Accessed: December 28, 2012
29. B.I. Rini, B. Escudier, P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial Lancet 378 2011 1931 1939